OSLO, Norway, Oct. 12, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:688176) has today unveiled the results of its Hexvix® (APL-1706) Phase III clinical trial in China. A presentation scheduled for today at the 43rd Congress of the Société Internationale d'Urologie (SIU), confirms that, in a Chinese population, Hexvix blue light cystoscopy (BLC®) outperformed white light cystoscopy (WLC) in the detection of bladder cancer, particularly in cases of carcinoma in situ (CIS), and exhibited good tolerability.
Read more at prnewswire.comPositive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here